TOP ONCOLOGY CRO
EXPERTS IN CLINICAL ONCOLOGY
QUALITY ONCOLOGY TRIAL MONITORING
home blog news careers français contact
QUALITY ONCOLOGY TRIAL MANAGEMENT


Why so many US oncology drug developers have enhanced their clinical trial performance by leveraging Canada for successful study expansion.


The Reverse Feasibility Program™

A Novel CRO Approach to Site Selection
& Patient Recruitment

Reverse Feasibility Program for 50% faster site start-up.A revolutionary approach to feasibility assessment that accelerates study start-up by matching your protocol with the current study needs of motivated and pre-qualified North American sites.

How it works...


Oncology Clinical Trial News

Scimega launches new Phase 2 Randomized, Open‑Label Study of a Novel Retroviral Replicating Vector Combined With Investigational Cytotoxic Compound versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma.

Scimega launches Phase 1 Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of novel mAb inhibitor of EMT in Subjects with an Advanced Solid Malignancy.

Scimega launches Canadian expansion of a Phase I/II, Multicenter,Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of a Cytidine Deaminase Inhibitor (CDAi) in Subjects with Myelodysplastic Syndromes (MDS).

See all news...

Upcoming Scimega Events

Clinical Operations in Oncology Trials – East Coast

July 15-16, 2015 in Boston

See all upcoming events...

Latest Podcast

Role of Patient Input for Oncology Drug Reviews

An interview with Marjorie Morrison, CEO of the Canadian Cancer Action Network

Listen to podcast...




Copyright © Scimega Research Inc. 2014. All rights reserved.
Privacy Policy

Oncology CRO   Clinical Trial Monitoring   Clinical Trial Management   Oncology Community